Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

Form 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report (date of earliest event reported):

March 22, 2005

 

 

SCOLR Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware   001-31982   91-1689591

(State or other jurisdiction

of incorporation)

   (Commission File No.)  

(I.R.S. Employer

Identification No.)

 

3625 132nd Avenue SE

Bellevue, WA 98006

(Address of principal executive offices)

 

(425) 373-0171

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 2.02 Results of Operations and Financial Condition.

 

On March 22, 2005, SCOLR Pharma, Inc. announced its financial results for 2004. A copy of the press release containing the announcement is attached as Exhibit 99.1. The information in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 as amended, or otherwise subject

 

Item 9.01 Financial Statements and Exhibits.

 

(c) Exhibits.

 

See Exhibit Index attached hereto.

 

2

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    SCOLR PHARMA, INC.
Dated: March 22, 2005   By:  

/s/ Daniel O. Wilds

       

Daniel O. Wilds

Chief Executive Officer and President

 

3

EXHIBIT INDEX

 

Exhibit No.
  

Description

99.1   Press Release of SCOLR Pharma dated March 22, 2005.

 

4